Sodium phosphate - Zeria

Drug Profile

Sodium phosphate - Zeria

Alternative Names: Monobasic sodium phosphate monohydrate/dibasic sodium phosphate anhydrous; Phosribbon Combination Granules; Z-521

Latest Information Update: 16 Apr 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Zeria
  • Class Laxatives; Phosphates
  • Mechanism of Action Phosphate-replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - X-linked dominant hypophosphataemic rickets; Osteomalacia
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hypophosphataemia
  • No development reported Osteomalacia; X-linked dominant hypophosphataemic rickets

Most Recent Events

  • 16 Apr 2015 No recent reports on development identified - Preregistration for Osteomalacia (In children) and X-linked dominant hypophosphataemic rickets (In children) in Japan (PO)
  • 25 Dec 2012 Registered for Hypophosphataemia in Japan (PO)
  • 15 May 2012 Preregistration for Osteomalacia (in children) in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top